Gland Pharma Limited (BOM:543245)

Market Cap	265.55B
Revenue (ttm)	56.17B
Net Income (ttm)	6.99B
Shares Out	n/a
EPS (ttm)	42.40
PE Ratio	38.02
Forward PE	28.25
Dividend	18.00 (1.14%)
Ex-Dividend Date	Aug 14, 2025

Volume	14,094
Average Volume	9,381
Open	1,566.55
Previous Close	1,580.75
Day's Range	1,566.55 - 1,595.00
52-Week Range	1,200.00 - 2,220.95
Beta	n/a
RSI	71.41
Earnings Date	May 20, 2025

About Gland Pharma

Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. The company engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company offers its products for various therapeutic categories, such as anti-malarial, anti-infectives, anti-neoplastic, blood ...

• Industry: Pharmaceutical Preparations
• Founded: 1978
• Employees: 4,286
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 543245

Financial Performance

In 2024, Gland Pharma's revenue was 56.17 billion, a decrease of -0.85% compared to the previous year's 56.65 billion. Earnings were 6.99 billion, a decrease of -9.57%.